Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | SGK1 | O00141 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 5/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | CDK2 | P24941 | 2/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.36 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.36 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7947642 | 0.69 | MPO (0.47) | ALDH1A1KDM4EGAAHPGDGLA | |
| SCHEMBL7960375 | 0.69 | KDM4E (0.36) | ALDH1A1KDM4EHPGDGLASMN1; SMN2 | |
| SCHEMBL4932531 | 0.67 | LTB4R (0.51) | ALDH1A1KDM4EGAARECQLMCL1 | |
| SCHEMBL2060224 | 0.62 | ADORA2A (0.50) | ALDH1A1KDM4EGAACDK1MAPK1 | |
| SCHEMBL27686623 | 0.61 | CDK1 (0.47) | ALDH1A1KDM4EGAAHPGDGLA | |
| SCHEMBL2060290 | 0.60 | ADORA2A (0.65) | ALDH1A1KDM4EGAACDK1MAPK1 | |
| SCHEMBL2060202 | 0.59 | ADORA2A (0.63) | ALDH1A1KDM4EGAACDK1MAPK1 | |
| SCHEMBL24038284 | 0.57 | APP (0.70) | ALDH1A1KDM4EGAAHPGDGLA | |
| SCHEMBL8410920 | 0.56 | NPSR1 (0.68) | ALDH1A1KDM4EGAAHPGDGLA | |
| SCHEMBL27393423 | 0.56 | RECQL (0.84) | RECQLMCL1SMN1; SMN2CDK5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6297250-B1 | USEFUL FOR INHIBITING TRANSPORT OF NUCLEOSIDES OR PURINES ACROSS CELL MEMBRANES, THEREBY TO POTENTIATE THE ACTIVITY OF VARIOUS CYTOTOXIC ANTITUMOR DRUGS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 2001-10-02 | — | — | US | claimed |
| US-20240166770-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF CELL-PENETRATING ANTIBODIES | YALE UNIVERSITY | 2024-05-23 | — | — | US | disclosed |
| WO-2021077070-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF CELL-PENETRATING ANTIBODIES | YALE UNIVERSITY (US) | 2021-04-22 | — | — | WO | disclosed |
| US-6297250-B1 | USEFUL FOR INHIBITING TRANSPORT OF NUCLEOSIDES OR PURINES ACROSS CELL MEMBRANES, THEREBY TO POTENTIATE THE ACTIVITY OF VARIOUS CYTOTOXIC ANTITUMOR DRUGS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 2001-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166770-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF CELL-PENETRATING ANTIBODIES | SLC29A1, SLC29A2, SLC7A1 | ALDH1A1 2004/4885KDM4E 2898/4885GAA 1261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.